<DOC>
	<DOCNO>NCT02936180</DOCNO>
	<brief_summary>Influenza , vaccine-preventable respiratory disease , rank 8th among cause death Canadian population . Among rheumatoid arthritis ( RA ) patient , incidence seasonal influenza serious influenza-related illness ( IRI ) increase . Despite high priority group target vaccination , diagnosis RA patient-specific factor ( i.e . old age , treatment , current smoking ) link impaired vaccination response . Thus burden influenza among people RA disproportionally high , intervention improve response influenza vaccination urgently need . Strategies optimize protection another vulnerable group , elderly , include use quadrivalent vaccine , high antigen dos , adjuvant . A high-dose , trivalent , inactivated influenza vaccine ( HD-TIV ) recently show similar safety profile standard dose vaccine ( SD-TIV ) improve immunogenicity protection adult ≥65 year age . Whether analogous strategy improve response influenza vaccine enhance protection people RA unknown . The investigator hypothesize use HD-influenza vaccine improve vaccine-induced protection ( i.e . seroconversion seroprotection ) people RA compare SD-influenza vaccine . The investigator propose conduct stratify , randomize , modify double blind , active-controlled trial ass immune response two commercial influenza vaccine contain different antigen dos individual RA .</brief_summary>
	<brief_title>Standard Versus High Dose Inactivated Influenza Vaccine RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Diagnosis seropositive RA ( rheumatoid factor ( RF ) and/or antiCCP antibody positive ) base 2010 ACREULAR criterion . 2 . At least 6 month treatment include antiTNF agent , abatacept , rituximab ( dose receive within previous 6 month ) and/or methotrexate . 3 . Informed consent form sign date . 4 . Able attend schedule visit comply trial procedure . 1 . Vaccination influenza 6 month precede trial vaccination . 2 . Systemic hypersensitivity egg , chicken protein , vaccine component , history lifethreatening reaction TIV vaccine contain substance . 3 . History GuillainBarré syndrome within six week previous influenza vaccination . 4 . Dementia cognitive condition could interfere trial procedure . 5 . Thrombocytopenia bleed disorder contraindicate IM vaccination ( accord treat rheumatologist ) . 6 . Current alcohol abuse drug addiction . 7 . Moderate severe acute illness without fever . If exists , vaccination defer individual medically stable and/or afebrile least 24 hour . 8 . Signs symptom acute infectious respiratory illness . If exists , vaccination defer symptom resolve . 9 . Pregnant woman ( rationale exclude group lack indication vaccination change maternal immune response pregnancy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Flu vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>